Clinical Trials Browser

Completed × Capecitabine × Breast × Clear all

NCT05064085 2026-04-06

Capecitabine In Combination With Cemiplimab In Patient With Metastatic Breast Cancer

Phase 1 Completed

Breast Neoplasms

NCT02767661 2026-02-27

MECCA

Phase 3 Completed

Breast Neoplasms

NCT03523585 2026-02-27

DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]

Phase 3 Completed

608 enrolled 17 charts

Breast Neoplasms

NCT01494662 2026-01-23

HKI-272 for HER2-Positive Breast Cancer and Brain Metastases

Phase 2 Completed

140 enrolled 32 charts

Breast Neoplasms

NCT06961331 2026-01-09

Real World-clinical Outcomes of Tucatinib, Trastuzumab, and Capecitabine Following Trastuzumab Deruxtecan (T-DXd) for the Treatment of HER2-positive Metastatic Breast Cancer.

Breast Neoplasms

NCT03371017 2025-11-12

IMpassion132

Phase 3 Completed

595 enrolled 37 charts

Triple Negative Breast Neoplasms

NCT04664829 2025-09-23

The Role of Bexarotene in Inducing Susceptibility to Chemotherapy in Metastatic TNBC

Phase 1 Completed

Triple Negative Breast Neoplasms

NCT02514681 2025-09-10

PRECIOUS

Phase 3 Completed

Breast Neoplasms

NCT07143097 2025-08-27

Capecitabine as Maintenance Therapy vs Observation in Early-stage Triple-negative Breast Cancer

Phase 2 Completed

Triple Negative Breast Neoplasms

NCT05007106 2025-08-14

KEYVIBE-005

Phase 2 Completed

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT01354522 2025-06-15

TAC Versus TCX as Adjuvant Treatment for High-risk Her2-Negative Breast Cancer

Phase 3 Completed

Breast Neoplasms

NCT03997968 2024-12-24

A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors

Phase 1/2 Completed

BreastGastrointestinalGynecologicHead & NeckLymphoidPlasma cellSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Head and Neck Neoplasms, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Lymphoma, Mantle-Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04276493 2024-12-06

Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab

Phase 1/2 Completed

BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms

NCT03487666 2024-12-03

OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease

Phase 2 Completed

45 enrolled 15 charts

Triple Negative Breast Neoplasms

NCT02892123 2024-11-27

Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers

Phase 1 Completed

BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Stomach Neoplasms

NCT02009449 2024-11-15

IVY

Phase 1 Completed

BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT03901339 2024-10-21

TROPiCS-02

Phase 3 Completed

543 enrolled 25 charts 2 FDA

Breast Neoplasms

NCT03839823 2024-10-09

RIGHT Choice

Phase 2 Completed

222 enrolled 17 charts

Breast Neoplasms

NCT03355157 2024-10-01

PADMA

Phase 4 Completed

Breast Neoplasms, Patient Acceptance of Health Care

NCT02028507 2024-09-25

PEARL

Phase 3 Completed

693 enrolled 40 charts

Breast Neoplasms

NCT04464174 2024-07-26

PATHFINDER

Phase 2 Completed

Triple Negative Breast Neoplasms

NCT03887130 2024-04-30

Study of Oral Vinorelbine Plus Capecitabine Versus Taxane-gemcitabine Combinations as 1st Line Chemotherapy in Metastatic Breast Cancer

Phase 2 Completed

152 enrolled 14 charts

Breast Neoplasms

NCT02954055 2024-02-26

METEORA-II

Phase 2 Completed

140 enrolled 11 charts

Breast Neoplasms, Neoplasm Metastasis

NCT03853707 2024-02-20

Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer

Phase 1/2 Completed

28 enrolled 12 charts

Triple Negative Breast Neoplasms

NCT04350021 2024-01-17

METRO

Breast Cancer Metastatic

NCT01387295 2023-12-11

Intra-hepatic Chemotherapy in Patients With Liver Metastases From Breast Cancer and Limited Extrahepatic Disease

Phase 2 Completed

38 enrolled 11 charts

Breast Neoplasms

NCT02754011 2023-12-07

GEP14-LEECAP

Phase 1 Completed

Breast Neoplasms, Neoplasm Metastasis

NCT01300962 2023-12-04

Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer

Phase 1 Completed

Breast Neoplasms, Neoplasm Metastasis

NCT03958721 2023-11-27

Capecitabine and Radiotherapy in the Adjuvant Treatment of Resistant Breast Cancer

Phase 1 Completed

Resistant Breast Cancer

NCT03262935 2023-10-19

TULIP

Phase 3 Completed

437 enrolled 17 charts

Breast Neoplasms

NCT02614794 2023-08-14

HER2CLIMB

Phase 2 Completed

612 enrolled 30 charts 3 FDA

Brain Neoplasms, Breast Neoplasms

NCT01439282 2023-06-22

Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer

Phase 2 Completed

77 enrolled 9 charts

Breast Neoplasms

NCT03084939 2023-05-06

Efficacy and Safety of Trastuzumab Emtansine in Chinese Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer

Phase 3 Completed

Breast Neoplasms

NCT00129935 2023-03-31

EC Followed Docetaxel Versus ET Followed Capecitabine as Adjuvant Chemotherapy for Node Positive Operable Breast Cancer

Phase 3 Completed

1,384 enrolled 22 charts

Breast Neoplasms

NCT00130533 2023-03-31

Maintenance Treatment With Capecitabine Versus Observation in Breast Cancer Patients

Phase 3 Completed

876 enrolled 24 charts

Breast Neoplasms

NCT04366713 2023-02-10

A Study to Characterize Colon Pathology in Patients With HER2 Amplified Breast Cancer Treated With Neratinib

Phase 2 Completed

6 enrolled 8 charts

Breast Neoplasms

NCT03462251 2023-01-19

RIBBIT

Phase 3 Completed

Breast Neoplasms

NCT05052437 2023-01-10

PK and Drug Interaction Study of Utidelone Plus Capecitabine in Patients With Advanced Breast Cancer

Phase 1 Completed

Breast Neoplasms

NCT03383679 2022-11-21

START

Phase 2 Completed

Breast Cancer Female

NCT00433589 2022-11-17

MINDACT

Phase 3 Completed

Breast Neoplasms, Carcinoma, Ductal, Breast, Carcinoma, Lobular

NCT00807859 2022-11-08

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

Phase 1 Completed

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

NCT03473639 2022-11-01

Breast49

Phase 1 Completed

Breast Neoplasms

NCT02574455 2022-06-15

ASCENT

Phase 3 Completed

529 enrolled 23 charts 2 FDA

Breast Neoplasms

NCT01498458 2022-06-10

PazoX

Phase 1 Completed

9 enrolled 15 charts

Breast Neoplasms

NCT03518242 2022-06-08

Molecular Profile of Breast Cancer in Ugandan Patients With Stage IIB-III Breast Cancer

Phase 1 Completed

Breast Cancer Female

NCT01095003 2022-04-28

Trial of Vinflunine Plus Capecitabine in Advanced Breast Cancer

Phase 3 Completed

770 enrolled 13 charts

Breast Neoplasms

NCT02000882 2022-02-07

STAR Cape+BKM120 MBC With Brain Met

Phase 2 Completed

10 enrolled 11 charts

Brain Neoplasms, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02555657 2021-12-10

KEYNOTE-119

Phase 3 Completed

622 enrolled 26 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT01802970 2021-10-08

Safety and Blood Immune Cell Study of Anakinra Plus Physician's Chemotherapy Choice in Metastatic Breast Cancer Patients

Phase 1 Completed

Breast Neoplasms

NCT01808573 2021-06-11

NALA

Phase 3 Completed

621 enrolled 21 charts 3 FDA

HER2+ Metastatic Breast Cancer (MBC)